Literature DB >> 26420615

Biobanking of Cerebrospinal Fluid for Biomarker Analysis in Neurological Diseases.

Eline A J Willemse1, Charlotte E Teunissen2.   

Abstract

Cerebrospinal fluid (CSF) reflects pathophysiological aspects of neurological diseases, where neuroprotective strategies and biomarkers are urgently needed. Therefore, biobanking is very relevant for biomarker discovery and evaluation for these neurological diseases.An important aspect of CSF biobanking is quality control, needed for e.g. consistent patient follow-up and the exchange of patient samples between research centers. Systematic studies to address effects of pre-analytical and storage variation on a broad range of CSF proteins are needed and initiated.Important features of CSF biobanking are intensive collaboration in international networks and the tight application of standardized protocols. The current adoption of standardized protocols for CSF and blood collection and for biobanking of these samples, as presented in this chapter, enables biomarker studies in large cohorts of patients and controls.In conclusion, biomarker research in neurodegenerative diseases has entered a new era due to the collaborative and multicenter efforts of many groups. The streamlining of biobanking procedures, including sample collection, quality control, and the selection of optimal control groups for investigating biomarkers is an important improvement to perform high quality biomarker studies.

Entities:  

Keywords:  Biobank; Biomarkers; Cerebrospinal fluid; Neurology; Quality control

Mesh:

Substances:

Year:  2015        PMID: 26420615     DOI: 10.1007/978-3-319-20579-3_7

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  3 in total

1.  Intraventricular Hemorrhage Clearance in Human Neonatal Cerebrospinal Fluid: Associations With Hydrocephalus.

Authors:  Kelly B Mahaney; Chandana Buddhala; Mounica Paturu; Diego Morales; David D Limbrick; Jennifer M Strahle
Journal:  Stroke       Date:  2020-05-13       Impact factor: 7.914

2.  Effects of ex vivo ischemia time and delayed processing on quality of specimens in tissue biobank.

Authors:  Dan Guo; Anqi Wang; Ting Xie; Sumei Zhang; Dingyan Cao; Jian Sun
Journal:  Mol Med Rep       Date:  2020-09-10       Impact factor: 2.952

3.  A Cystatin C Cleavage ELISA Assay as a Quality Control Tool for Determining Sub-Optimal Storage Conditions of Cerebrospinal Fluid Samples in Alzheimer's Disease Research.

Authors:  Kathleen Mommaerts; Eline A J Willemse; Monica Marchese; Catherine Larue; Wiesje M van der Flier; Fay Betsou; Charlotte E Teunissen
Journal:  J Alzheimers Dis       Date:  2021       Impact factor: 4.472

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.